Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
ARCT(NASDAQ:ARCT) Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children
Arcturus Therapeutics to Attend Upcoming Investor Conferences
ARCTSAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conferences: Citi’s 2025 Biopharma Back to School Conference (Fireside Chat) Tuesday, September 2, 2025 (11:15 a.m. ET) 2025 Wells Fargo Healthcare Conference (
Arcutis to Present at Upcoming Investor Conferences
ARCTArcutis today announced that management will participate in three upcoming investor conferences.
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
ARCTSAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate updates. “The Company continues to advance and provide meaningful clinical data across our mRNA therapeutics and vaccines pipeline,
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
ARCTArcutis today reported financial results for the quarter ended June 30, 2025, and provided a business update.
Scotiabank Initiates Coverage On Arcturus Therapeutics with Sector Outperform Rating, Announces Price Target of $32
ARCTWells Fargo Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $45
ARCTDemystifying Arcturus Therapeutics: Insights From 7 Analyst Reviews
ARCTCanaccord Genuity Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $66
ARCT12 Health Care Stocks Moving In Tuesday's Pre-Market Session
ARCTArcturus Therapeutics Q1 EPS $(0.52) Beats $(1.33) Estimate, Sales $29.38M Beat $27.88M Estimate
ARCTHC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $60 Price Target
ARCTCanaccord Genuity Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $68
ARCTBeyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock
ARCTHC Wainwright & Co. Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $60
ARCTCantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight
ARCTWells Fargo Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $50
ARCTArcturus Therapeutics Q4 2024 GAAP EPS $(1.11) Misses $(0.44) Estimate, Sales $22.800M Miss $44.650M Estimate
ARCTHC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $63 Price Target
ARCTBreaking Down Arcturus Therapeutics: 5 Analysts Share Their Views
ARCTHC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $63 Price Target
ARCTEuropean Commission Approves CSL And Arcturus Therapeutics' KOSTAIVE COVID-19 Vaccine, First sa-mRNA Vaccine Authorized For Adults In Europe
ARCTHC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $63 Price Target
ARCTArcturus Therapeutics Initiates Phase 1 H5N1 Flu Vaccine Trial
ARCTMeiji Seika Pharma Invests In ARCALIS, Expects To Enhance Japan's mRNA Vaccine Infrastructure
ARCTCSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine
ARCT